Mammography screening does not save many women's lives, reports a new study. It just provides early diagnosis with no impact on mortality or it over diagnoses disease.
Mammography screening does not save many women's lives, reports a new study. It just provides early diagnosis with no impact on mortality or it over diagnoses disease.
Using DevCan 6.5.0, which the National Cancer Institute uses in estimating 10-year risk of diagnosis and 20-year risk of death, researchers at Dartmouth College developed a method to calculate the probability that a woman with screen-detected breast cancer has had her life saved by screening.
They determined that a 50-year-old woman has an estimated risk for having screen-detected breast cancer in the next 10 years of 1,910 per 100,000. Her observed 20-year risk for breast cancer is 990 per 100,000. Assuming that mammography reduces her risk for breast cancer by 20%, the risk for death without screening would be 1,240 per 100,000, suggesting that 250 per 100,000 women are spared. Thus, the likelihood that a woman with screen-detected breast cancer avoids death from her disease because of the screening is 13%. If screening mammography reduces breast cancer mortality by 5%, then the death benefit is only 3%. Analyses of women of different ages all yielded probability estimates below 25%.
Welch HG, Frankel BA. Likelihood that a woman with screen-detected breast cancer has had her "life saved" by that screening. Arch Intern Med. October 24, 2011. (Epub ahead of print.)
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Study finds pregnancy risks higher with ART in kidney transplant recipients
July 11th 2025Women with kidney transplants who conceive through assisted reproductive technology face increased risks of complications such as hypertension, preterm birth, and cesarean delivery, according to new research.
Read More
Trimethoprim–sulfamethoxazole not found to increase infant birth weight in HIV cases
July 9th 2025A recent randomized trial found no significant improvement in birth weight or key birth outcomes from antenatal trimethoprim–sulfamethoxazole prophylaxis in human immunodeficiency virus-positive pregnant women.
Read More